Biggest Differences between Right to Try and expanded acess

* Right to try doesn’t need an IRB
* Right to try blocks liability of all parties involved.
  + Medical Negligence Determinations, the Right to Try, and Expanded Access to Innovative Treatments Denise Meyerson

Paper Ideas in rank of easiest to hardest

1. Follow a single patient using expanded acess and note how long it takes for irb approval by physician and drug company approval.

Pro’s

-would be an interesting case study

-almost no info out on how long irb takes or drug approval would take. This is especially true now that irb only needs single irb member approval.

Con’s

-Only looking at one patient is kinda lame

2. Try to find two similar patients one using right to try the other using expanded access and talk about the timeline both took to get the drugs they need

Pro’s

-Can’t find anything like this in literature and would provide a quasi-direct comparison

Of two programs in practice.

Con’s

-I would suspect that the right to try system hasn’t really been put in practice at mount Sinai whereas the expanded access has. To look into right to try might have to compare it to other papers published or even worse cases listed on the right to try site.

3. Find a legal database and see if there have been / how many cases of medical malpractice have been brought into suit due to adverse events resulting from the use of investigational drugs.

Pro’s

-If we could show that their have been almost no suits brought up and that those that have been brought up were won by the doctor we can help show that the effects of blocking liability from right to try is reliable.

-for ny would have to use <https://www.health.ny.gov/regulations/foil/howto.htm> to request the database <https://www.nydoctorprofile.com/> this would allow me to get all malpractice suits against ny doctors or mount Sinai one’s

-if worth exploring could probably find better database

Con’s

-not really mount Sinai focused and doesn’t use the warehouse

4. Explore mount Sinai’s IRb policy. I would bet money if it mentions expanded access it requires a full committee approval when that’s no longer required. Could explore it’s policy and things like how often it meets. One really cool paper did a review of 100 irb’s it would be cool to do something similar but on a smaller scale.

5.Explore mount sinai’s expanded access irb approval rates and average length of time. This number doesn’t exist and would be very valuable.

Pro’s

-again no real numbers on this exist so would be valuable to see if we could get logs of irb meeting or make predictions from the warehouse

6. Explore health disparities in expanded access thought patient insurance policy and location.

Pro’s

-if 100% of people using expanded access aren’t on medicare or Medicaid in a database where 80% of patients are that shows that there is unequal levels of access.

-Can also use location as a rough proxy for wealth. If you live in a project your more likely to be less well off.

Con’s

-don’t know if insurance info is in the warehouse and using location as proxy alone would be week. This might be overcome if there is racial information included because that could also be used to show disparity.

7.Generate Cost information for experimental treatments based off patient’s billings.

Pro’s cost is unknown so it comes up a lot in articles would be interesting to try to quantify it.

Con’s I don’t think the datawarehouse would have this info so it would be tricky to link patients with billing info which I also don’t think is available.

DON’T NEED IRB IN RIGHT TO TRY NEED ONE PERSON IN IRB TO APPROVE AT MINAMUM SOME IRB PROCESSES MAY BE DIFFERENT. IF NOT IRB NEED TO PAY FOR OUTSIDE IRB.

-average time irb took

-amount of time drug company response took

-both factors in total time of right to try vs expanded acess not really covered

-Look at rate of irb approvals in mount Sinai system that is the paper. If we can use warehouse data or irb logs we can provide an element not really analyzed.

Title: Comparative analysis of treatment options available through the right to try legislation and the expanded access program.

Introduction:

Expanded access approval rate from Pfizer was 98% https://www.pfizer.com/purpose/medicine-access/compassionate-use.

Methods:

Using the Drugs@FDA database I opened the products.txt file through pandas to create a dataframe. Using that generated dataframe I created a list of all unique DrugNames. This gave me a collection of 7088 drugs that the FDA has approved. Then through the clinical trials database I downloaded all drugs listed in interventions for both trails listed as phase 3 that have statuses of either: not yet recruiting, recruiting, enroll by invitation, active not recruiting or suspended (but not including completed) and trails listed as available and/or approved for marketing in their expanded access program. From both these lists I found all unique drug entries and removed all those in the approved drugs@FDA database and those with the text phrase placebo. Because these databases are not linked it’s possible that this does not remove all the approved drugs to contain just the experimental drugs. However, this still provides value as an estimate of what is available.

Using PharmaGKB I downloaded a comprehensive drugs database. From this I created a python program that allowed for me to easily parse their database and query all drugs from Id’s, all Id’s from each drug and all the different terms used for each drug. This was done to create a more compressive list of all terms used for each drug such that one can quickly determine if a drug listed in the warehouse is novel or simply not the main name.

Results:

Discussion:

<https://www.ajmc.com/journals/evidence-based-oncology/2018/patient-centered-oncology-care-2017/weighing-the-merits-of-righttotry-laws-and-fdas-expanded-access-program>

1. Pennsylvania becomes the 38th state to pass right to try. Goldwater Institute website. goldwaterinstitute.org/article/pennsylvania-becomes-38th-state-to-pass-right-to-try/. Published October 13, 2017. Accessed January 16, 2018.  
  
2. Karlin-Smith S, Kim SM. Senate approves ‘right-to-try’ drug bill. Politico. politico.com/story/2017/08/03/senate-right-to-try-drug-bill-241293. Published August 3, 2017. Accessed January 16, 2018.  
  
3. FDA Expanded Access (Compassionate Use). FDA website. fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534121/>

1. White House. Readout of the vice president’s meeting with right to try advocates. <https://www.whitehouse.gov/the-press-office/2017/02/07/readout-vice-presidents-meeting-right-try-advocates>. Accessed 15 Feb 2017.

2. U.S. Food and Drug Administration. Expanded access INDs and protocols 2009–2015. <http://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/ucm443572.htm>. Accessed 15 Feb 2017.

3. U.S. Food and Drug Administration. Expanded access (compassionate use) <https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm>. Accessed 23 June 2017.

4. U.S. Food and Drug Administration. Charging for investigational drugs under an IND—questions and answers, guidance for industry. <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM351264.pdf> Accessed 23 June 2017.

5. Jarow JP, Lurie P, Ikenberry SC, Lemery S. Overview of FDA’s expanded access program for investigational drugs. Ther Innov Regul Sci. 2017;51(2):177–179. doi: 10.1177/2168479017694850.[[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443564/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28553565)] [[Cross Ref](https://dx.doi.org/10.1177%2F2168479017694850)]

6. Falit BP, Gross CP. Access to experimental drugs for terminally ill patients. JAMA. 2008;300:2793–2795. doi: 10.1001/jama.2008.828.[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/19088356)] [[Cross Ref](https://dx.doi.org/10.1001%2Fjama.2008.828)]

7. Whitfield K, Huemer K-H, Winter D, et al. Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries. Trials. 2010;11:104. doi: 10.1186/1745-6215-11-104. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997627/)][[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/21073691)] [[Cross Ref](https://dx.doi.org/10.1186%2F1745-6215-11-104)]

8. Caplan A, Ray A. The ethical challenges of compassionate use. JAMA. 2016;315(10):979–980. doi: 10.1001/jama.2016.0416.[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26868205)] [[Cross Ref](https://dx.doi.org/10.1001%2Fjama.2016.0416)]

9. Welch MJ, Lally R, Miller JE, et al. The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials. Clin Trials. 2015;12(5):503–510. doi: 10.1177/1740774515597701. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662375/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26374681)] [[Cross Ref](https://dx.doi.org/10.1177%2F1740774515597701)]

10. Bunnik EM, Aarts N, van de Vathorst S. The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications. J Pharm Policy Pract. 2017;10:10. doi: 10.1186/s40545-017-0100-3. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320715/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28239479)][[Cross Ref](https://dx.doi.org/10.1186%2Fs40545-017-0100-3)]

11. Darrow JJ, Sarpatwari JD, Avorn J, Kesselheim AS. Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med. 2015;372:279–286. doi: 10.1056/NEJMhle1409465.[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25587952)] [[Cross Ref](https://dx.doi.org/10.1056%2FNEJMhle1409465)]

12. Zettler PJ, Greely HT. The strange allure of state “right-to-try” laws. JAMA Intern Med. 2014;174(12):1885–1886. doi: 10.1001/jamainternmed.2014.5767. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/25264589)] [[Cross Ref](https://dx.doi.org/10.1001%2Fjamainternmed.2014.5767)]

13. Mackey TK, Schoenfeld VJ. Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. BMC Med. 2016;14:17. doi: 10.1186/s12916-016-0568-8. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739083/)][[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26843367)] [[Cross Ref](https://dx.doi.org/10.1186%2Fs12916-016-0568-8)]

14. Zettler PJ. Compassionate use of experimental therapies: who should decide? EMBO Mol Med. 2015 [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604679/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/26202382)]

15. Jarow JP, Lemery S, Bugin K, Lowy N. Ten-year experience for the Center for Drug Evaluation and Research, Part 2: FDA’s role in ensuring patient safety. Ther Innov Regul Sci. 2017;51(2):246–249. doi: 10.1177/2168479016679214. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443559/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/28553566)][[Cross Ref](https://dx.doi.org/10.1177%2F2168479016679214)]

16. Friedlaender J. The proposed federal ‘Right-To-Try’ law is not the answer for critically ill patients. Health Affairs Blog. <http://healthaffairs.org/blog/2016/09/27/the-proposed-federal-right-to-try-law-is-not-the-answer-for-critically-ill-patients/>. Accessed 15 Feb 2017.

17. Downing NS, Shah ND, Neiman JH, Aminawung JA, Krumholz HM, Ross JS. Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals. Trials. 2016;17(1):1. doi: 10.1186/s13063-016-1322-4. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832528/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/27079511)] [[Cross Ref](https://dx.doi.org/10.1186%2Fs13063-016-1322-4)]

18. Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. JAMA. 2014;311(4):368–377. doi: 10.1001/jama.2013.282034. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144867/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24449315)] [[Cross Ref](https://dx.doi.org/10.1001%2Fjama.2013.282034)]

19. Gifford AL, Cunningham WE, Heslin KC, Andersen RM, Nakazono T, Lieu DK, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med. 2002;346(18):1373–1382. doi: 10.1056/NEJMsa011565. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/11986412)][[Cross Ref](https://dx.doi.org/10.1056%2FNEJMsa011565)]

20. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med. 2002;162(15):1682–1688. doi: 10.1001/archinte.162.15.1682.[[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/12153370)] [[Cross Ref](https://dx.doi.org/10.1001%2Farchinte.162.15.1682)]

21. Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12:116. doi: 10.1186/1479-5876-12-116. [[PMC free article](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030525/)] [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/24885479)] [[Cross Ref](https://dx.doi.org/10.1186%2F1479-5876-12-116)]

22. Fromer MJ. Road to successful use of real-world evidence for drug development is long and rocky, ASCO report. <http://www.ascopost.com/issues/july-25-2016/road-to-successful-use-of-real-world-evidence-for-drug-development-is-long-and-rocky>. Accessed 15 Feb 2017.

very similar to what I’m doing

<https://jech.bmj.com/content/jech/72/7/557.full.pdf> - high level impact on expanded acess

<http://journals.sagepub.com/doi/abs/10.1177/2168479018759661> - talks about IRB’s very valuable (analyzed data set of 100 irb’s to see what it took(

Could be intressting to explore impact of one IRB member review policy

Could be cool to search through 100 irb’s with nlp

OOOO could hit up mount Sinai irb to see if we could review their records of drug access and from there acess the acceptance rate. This is novel because no estimates of this number exists.

Possible we could bypass this through looking at patient info in data warehouse

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2684626> - shows a lot of drugs in expanded acess program get approved soon after

<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2684626> - very similar to what we were doing originally looking at the approved drugs in drugs@fda and those in expanded acess in clincialtrials. They simply used this info to provide a timeframe about how long it took from expanded access to approval. Coolest thing is they used the expanded access flag as if it had value which we stated didn’t.

[**https://www.nature.com/articles/nbt0418-294**](https://www.nature.com/articles/nbt0418-294) **- nothing really intressting**

[**https://www.tandfonline.com/doi/pdf/10.1080/13543784.2018.1430137?needAccess=true**](https://www.tandfonline.com/doi/pdf/10.1080/13543784.2018.1430137?needAccess=true)

**-good sources descriptions**

Federal Right-to-Try Legislation — Threatening the FDA’s Public Health Mission Steven Joffe, M.D., M.P.H., and Holly Fernandez Lynch, J.D., M.B.E

-most famous paper on topic probs

[**https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821240/**](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821240/)

**-right to try v v bad**

[**https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2669909**](https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2669909)

**-righ try bad**

Exploring length of time irb takes

<https://www.ncbi.nlm.nih.gov/pubmed/29902956>

<https://www.ncbi.nlm.nih.gov/pubmed/27429877>

<https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12255>

-comparison chart of right to try and expanded access best I’ve found so far in contrasting the two programs.

-best paper I found